首页|期刊导航|医学分子生物学杂志|门窦血管病诊疗研究进展

门窦血管病诊疗研究进展OA

Advances in Diagnosis and Management of Porto-Sinusoidal Vascu-lar Disease

中文摘要英文摘要

门窦血管病(porto-sinusoidal vascular disease,PSVD)是近年来新界定的肝脏血管性疾病,其特征为门脉-窦性微循环结构损伤及由此引起的门静脉高压相关并发症.随着病理学、转录组学与遗传学研究以及医学影像技术的发展,针对PSVD 的诊断识别已由单纯临床排除性诊断进展为采用病理学、分子生物学和无创检查等多种手段进行综合评估的精准诊疗模式.文章围绕 PSVD 的病理生理学与分子机制、病理学基础、临床表现、分子与无创诊断线索及治疗策略等方面进行综述,并对分层诊断模型与机制导向治疗的研究方向进行展望.

Porto-sinusoidal vascular disease(PSVD)is a recently redefined vascular liver disor-der characterized by structural injury of the porto-sinusoidal microcirculation and consequent compli-cations related to portal hypertension.With advances in histopathology,transcriptomics,genetic studies,and medical imaging technologies,the diagnostic approach to PSVD has evolved from a pri-marily exclusion-based clinical diagnosis toward a precision-oriented strategy integrating pathologi-cal assessment,molecular profiling,and non-invasive evaluation.This review summarizes recent progress in the pathophysiological and molecular mechanisms,histopathological features,clinical manifestations,molecular and non-invasive diagnostic clues,and therapeutic strategies of PSVD.Furthermore,we discuss future perspectives regarding the development of stratified diagnostic mod-els and mechanism-directed therapeutic approaches for this disease.

边昊;魏红山

首都医科大学附属北京地坛医院消化内科 北京市,100015首都医科大学附属北京地坛医院消化内科 北京市,100015||首都医科大学HBV感染、临床治愈与免疫联合实验室 北京市,100015

医药卫生

门窦血管病门静脉高压分子机制分子标志物

porto-sinusoidal vascular diseaseportal hypertensionmolecular mechanismsbio-markers

《医学分子生物学杂志》 2026 (5)

587-591,5

首医HBV感染、临床治愈和免疫联合实验室(No.JL202508),首都卫生发展科研专项重点项目子课题(No.首发2024-1-4081) This work was supported by grants from the HBV Infection,Clinical Cure and Immunotherapy Joint Laboratory of Capital Medical University(No.JL202508)and the Key Program Subproject of the Capital Health Research and Development Special Fund(No.2024-1-4081).

10.3870/j.issn.1672-8009.2026.05.014

评论